Literature DB >> 8125529

Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules.

L Di Renzo1, J Avila-Cariño, E Klein.   

Abstract

Six Epstein Barr virus (EBV) genome-carrying Burkitt lymphoma (BL) cultures (P3HR-1, Raji, Akata, Daudi, Rael and Jijoye) were induced to enter the lytic cycle. Phorbol esther (TPA), n-butyrate, 5-azacytidine (5AzaC) or anti-IgG were used according to their known inducing capacity on these cell lines. Concomitantly with the appearance of the viral early antigens (EA) in a proportion of cells, the expression of major histocompatibility complex (MHC) class II antigens increased in the cultures. On P3HR-1 and Raji cells class I expression also increased. The enhancement of MHC expression correlated with the efficiency of induction and required only an early event of the viral lytic cycle. Treatment of 3 EBV-negative lymphoma lines (BJAB, Ramos and BL41) with TPA plus n-butyrate or 5AzaC did not influence MHC expression. Moreover, BL lines which carry the EBV genome after having been infected in vitro and which cannot be induced for the viral lytic cycle did not change MHC expression after treatment with the inducing agents. In mixed cultures the allo-stimulatory capacity of induced cells with elevated MHC expression was stronger compared to the untreated ones.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8125529     DOI: 10.1016/0165-2478(93)90008-p

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  9 in total

1.  Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.

Authors:  Ulas Darda Bayraktar; Luis A Diaz; Brittany Ashlock; Ngoc Toomey; Lisa Cabral; Soley Bayraktar; Denise Pereira; Dirk P Dittmer; Juan Carlos Ramos
Journal:  Leuk Lymphoma       Date:  2013-08-28

2.  Role of ATM in the formation of the replication compartment during lytic replication of Epstein-Barr virus in nasopharyngeal epithelial cells.

Authors:  Pok Man Hau; Wen Deng; Lin Jia; Jie Yang; Tatsuya Tsurumi; Alan Kwok Shing Chiang; Michael Shing-Yan Huen; Sai Wah Tsao
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

3.  n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids.

Authors:  G A Böhmig; P M Krieger; M D Säemann; C Wenhardt; E Pohanka; G J Zlabinger
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

4.  Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms.

Authors:  Stuart Prince; Sinead Keating; Ceri Fielding; Paul Brennan; Eike Floettmann; Martin Rowe
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.

Authors:  Sinéad Keating; Stuart Prince; Matthew Jones; Martin Rowe
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

6.  Distinct ex vivo susceptibility of B-cell subsets to epstein-barr virus infection according to differentiation status and tissue origin.

Authors:  Marcus Dorner; Franziska Zucol; Christoph Berger; Rahel Byland; Gregory T Melroe; Michele Bernasconi; Roberto F Speck; David Nadal
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

Review 7.  Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma.

Authors:  Pok Man Hau; Hong Lok Lung; Man Wu; Chi Man Tsang; Ka-Leung Wong; Nai Ki Mak; Kwok Wai Lo
Journal:  Front Oncol       Date:  2020-05-14       Impact factor: 6.244

8.  Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds.

Authors:  Giulia Matusali; Giuseppe Arena; Alessandra De Leo; Livia Di Renzo; Elena Mattia
Journal:  Mol Cancer       Date:  2009-03-09       Impact factor: 27.401

9.  Inhibition of Poly(ADP-ribose)polymerase impairs Epstein Barr Virus lytic cycle progression.

Authors:  Stefania Mattiussi; Italo Tempera; Giulia Matusali; Giulia Mearini; Luisa Lenti; Silvia Fratarcangeli; Luciana Mosca; Maria D'Erme; Elena Mattia
Journal:  Infect Agent Cancer       Date:  2007-10-11       Impact factor: 2.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.